Abbott Labs Glaukos: Which Stock Is Best to Buy in 2026
In 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
Yearly performance of total market index funds provides a broad view of winners and laggards. Use these insights to adjust your exposure today.
28,196 articlesIn 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
June card spending rose 6.3% year over year, with wage gains across all income groups. The latest bofa consumer chief...
Microsoft faces a high-growth, high-capex path as AI investment accelerates. Here is a fresh take on whether to buy, ...
A long-running tariff regime faces a courtroom setback and a looming deadline. This week, policymakers weigh tougher ...
Electricity demand is rising fast, and this shifts the playing field for energy stocks. Learn how to identify what be...
A man breached the Mar-a-Lago perimeter and was killed in a confrontation with Secret Service and a local deputy. The...
As XPEL gears up for 2025 earnings insights, investors need a clear view of growth drivers, margin discipline, and po...
A young plaintiff testifies in a civil trial accusing major platforms of harming mental health, focusing on a compuls...
Solana SOL bounced back above a critical level as Bitcoin steadies, reviving a solana price prediction: just debate a...
Alibaba is emerging as a potential sleeper AI winner in 2026, trading at a discount while advancing open-source AI an...
A major fund recently trimmed its Centrus Energy stake, sending ripples through the market. This article breaks down ...
Federal officials order a Texas-based oil company to resume offshore California production under the Defense Producti...